Comprehensive Stock Comparison
Compare BridgeBio Oncology Therapeutics Inc. (BBOT) vs Genmab A/S (GMAB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | BBOT | Lower P/E (21.8x vs 23.2x) |
| Stability / Safety | BBOT | Beta 0.26 vs GMAB's 0.61 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | GMAB | +29.8% vs BBOT's -9.2% |
| Efficiency (ROA) | GMAB | 93.6% ROA vs BBOT's -23.7%, ROIC 22.2% vs -64.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer drugs targeting specific genetic mutations in tumors. It generates revenue primarily through research collaborations and licensing deals — with future income dependent on successful drug development and commercialization — though currently in pre-revenue stage as it advances its clinical pipeline. The company's competitive advantage lies in its specialized focus on difficult-to-target oncogenes like KRAS and PI3Kα, leveraging BridgeBio Pharma's broader platform for drug discovery and development.
Genmab is a biotechnology company that develops and commercializes antibody-based therapies for cancer and other serious diseases. It generates revenue primarily through product sales of its marketed antibodies like DARZALEX and teprotumumab, plus significant royalties and milestone payments from partnerships with pharmaceutical companies like Johnson & Johnson. The company's key advantage is its proprietary antibody technology platforms — particularly its DuoBody bispecific antibody platform — which enable it to create differentiated therapies with improved efficacy and safety profiles.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
GMAB leads in 2 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 3 categories are tied.
Financial Metrics (TTM)
GMAB and BBOT operate at a comparable scale, with $14.0B and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.0B |
| EBITDAEarnings before interest/tax | -$124M | $5.3B |
| Net IncomeAfter-tax profit | -$115M | $6.6B |
| Free Cash FlowCash after capex | -$96M | $2.9B |
| Gross MarginGross profit ÷ Revenue | — | +94.3% |
| Operating MarginEBIT ÷ Revenue | — | +36.2% |
| Net MarginNet income ÷ Revenue | — | +46.8% |
| FCF MarginFCF ÷ Revenue | — | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -81.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | -66.7% |
Valuation Metrics
At 15.4x trailing earnings, GMAB trades at a 30% valuation discount to BBOT's 21.8x P/E.
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| Market CapShares × price | $794M | $18.1B |
| Enterprise ValueMkt cap + debt − cash | $793M | $16.7B |
| Trailing P/EPrice ÷ TTM EPS | 21.80x | 15.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 23.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.53x |
| EV / EBITDAEnterprise value multiple | — | 14.90x |
| Price / SalesMarket cap ÷ Revenue | — | 5.34x |
| Price / BookPrice ÷ Book value/share | 0.88x | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | 15.15x |
Profitability & Efficiency
GMAB delivers a 114.2% return on equity — every $100 of shareholder capital generates $114 in annual profit, vs $-26 for BBOT. On the Piotroski fundamental quality scale (0–9), GMAB scores 5/9 vs BBOT's 4/9, reflecting solid financial health.
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | +114.2% |
| ROA (TTM)Return on assets | -23.7% | +93.6% |
| ROICReturn on invested capital | -64.9% | +22.2% |
| ROCEReturn on capital employed | -83.3% | +18.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$2M | -$8.8B |
| Cash & Equiv.Liquid assets | $2M | $9.9B |
| Total DebtShort + long-term debt | $0 | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | — | 48.21x |
Total Returns (with DRIP)
A $10,000 investment in BBOT five years ago would be worth $9,843 today (with dividends reinvested), compared to $8,383 for GMAB. Over the past 12 months, GMAB leads with a +29.8% total return vs BBOT's -9.2%. The 3-year compound annual growth rate (CAGR) favors BBOT at -0.5% vs GMAB's -7.8% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| YTD ReturnYear-to-date | -18.4% | -7.5% |
| 1-Year ReturnPast 12 months | -9.2% | +29.8% |
| 3-Year ReturnCumulative with dividends | -1.6% | -21.6% |
| 5-Year ReturnCumulative with dividends | -1.6% | -16.2% |
| 10-Year ReturnCumulative with dividends | -1.6% | +138.4% |
| CAGR (3Y)Annualised 3-year return | -0.5% | -7.8% |
Risk & Volatility
BBOT is the less volatile stock with a 0.26 beta — it tends to amplify market swings less than GMAB's 0.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GMAB currently trades 83.1% from its 52-week high vs BBOT's 67.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.26x | 0.61x |
| 52-Week HighHighest price in past year | $14.87 | $35.43 |
| 52-Week LowLowest price in past year | $8.50 | $17.24 |
| % of 52W HighCurrent price vs 52-week peak | +67.5% | +83.1% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 38.3 |
| Avg Volume (50D)Average daily shares traded | 267K | 1.5M |
Analyst Outlook
Wall Street rates BBOT as "Buy" and GMAB as "Buy". Consensus price targets imply 132.6% upside for BBOT (target: $23) vs 37.6% for GMAB (target: $41).
| Metric | BBOTBridgeBio Oncolog… | GMABGenmab A/S |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $23.33 | $40.50 |
| # AnalystsCovering analysts | 2 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 24 | Feb 26 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 118.06 | +18.1% |
| Genmab A/S (GMAB) | 100 | 113.59 | +13.6% |
BridgeBio Oncology … (BBOT) returned -2% over 5 years vs Genmab A/S (GMAB)'s -16%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | $0.00 | $0.00 | — |
| Genmab A/S (GMAB) | $1.1B | $21.5B | +1799.8% |
Genmab A/S's revenue grew from $1.1B (2015) to $21.5B (2024) — a 38.7% CAGR.
Chart 3P/E Ratio History — 8 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Genmab A/S (GMAB) | 9.3 | 1.7 | -81.7% |
Genmab A/S has traded in a 2x–9x P/E range over 8 years; current trailing P/E is ~15x.
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | -0 | 0.46 | +22004.8% |
| Genmab A/S (GMAB) | 1.26 | 12.14 | +863.5% |
Genmab A/S's EPS grew from $1.26 (2015) to $12.14 (2024) — a 29% CAGR.
Chart 5Free Cash Flow — 5 Years
BridgeBio Oncology Therapeutics Inc. generated $-1M FCF in 2024. Genmab A/S generated $8B FCF in 2024 (+284% vs 2021).
BBOT vs GMAB: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BBOT or GMAB a better buy right now?
Genmab A/S (GMAB) offers the better valuation at 15.4x trailing P/E (23.2x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BBOT or GMAB?
On trailing P/E, Genmab A/S (GMAB) is the cheapest at 15.4x versus BridgeBio Oncology Therapeutics Inc. at 21.8x.
03Which is the better long-term investment — BBOT or GMAB?
Over the past 5 years, BridgeBio Oncology Therapeutics Inc. (BBOT) delivered a total return of -1.6%, compared to -16.2% for Genmab A/S (GMAB). A $10,000 investment in BBOT five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: GMAB returned +138.4% versus BBOT's -1.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BBOT or GMAB?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc. (BBOT) is the lower-risk stock at 0.26β versus Genmab A/S's 0.61β — meaning GMAB is approximately 139% more volatile than BBOT relative to the S&P 500.
05Which has better profit margins — BBOT or GMAB?
Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus 0.0% for BridgeBio Oncology Therapeutics Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31.1% versus 0.0% for BBOT. At the gross margin level — before operating expenses — GMAB leads at 95.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BBOT or GMAB more undervalued right now?
Analyst consensus price targets imply the most upside for BBOT: 132.6% to $23.33.
07Which pays a better dividend — BBOT or GMAB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BBOT or GMAB better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc. (BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.26)). Both have compounded well over 10 years (BBOT: -1.6%, GMAB: +138.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BBOT and GMAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BBOT is a small-cap quality compounder stock; GMAB is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.